Calcium sensitizer levosimendan and piperphentonamne: Research advances / 国际药学研究杂志

ABSTRACT

Calcium sensitizer levosimendan has good clinical effect for heart failure patients with long-term administration of β-receptor blocker. The efficiency of levosimendan combined with digoxigenin is similar to that of levosimendan alone in treatment of heart failure. Compared with oral administration, the intravenous route s more effective. Administrating levosimendan for patients after heart surgery can shorten the recovery time and decrease the incidence of atrial fibrillation. Levosimendan also has cardioprotective effects on myocardium injured by ischemia and reperfusion. Piperphentonamine (PPTA) also has the effects of cardioprotection. Phase I clinical trial for PPTA has been finished in 127 healthy volunteers. The result shows PPTA has better tolerance and the human pharmacokinetic parameters in healthy subjects are in accordance with animal. The safety and efficacy of PPTA need o be defined by further clinical trials. This article summaries the clinical research advances related to calcium sensitizers levosimendan and piperphentonamine in recent years.